MicroRNA-224 is implicated in lung cancer pathogenesis through targeting Caspase-3 and Caspase-7

Oncotarget

Volumn 6, Issue 26, 2015, Pages 21802-21815

  Cui, Ri ^a,d   Kim, Taewan ^b   Fassan, Matteo ^a,c   Meng, Wei ^a   Sun, Hui Lung ^a   Jeon, Young Jun ^a   Vicentini, Caterina ^e   Tili, Esmerina ^a,f   Peng, Yong ^g   Scarpa, Aldo ^e   Liang, Guang ^h   Zhang, Yong Kui ^d   Chakravarti, Arnab ^a   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d The Zhoushan Hospital of Wenzhou Medical University   (China)

^e UNIVERSITY OF VERONA   (Italy)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g SICHUAN UNIVERSITY   (China)

^h WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Caspase 3; Caspase 7; Lung cancer; MiR 224

Indexed keywords

CASPASE 3; CASPASE 7; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 224; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN; MESSENGER RNA; MIRN224 MICRORNA, HUMAN; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; NON SMALL CELL LUNG CANCER; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; 3' UNTRANSLATED REGION; CELL MOTION; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 7; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941241946     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5224     Document Type: Article

References (47)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
2. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003; 113:673-676.
3. Di Leva G and Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev. 2013; 23:3-11.
4. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev. 2005; 15:410-415.
5. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-866.
6. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM and Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9:189-198.
7. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and Takahashi T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005; 65:9628-9632.
8. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G and Croce CM. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009; 16:498-509.
9. Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H, Kim T, Suh SS, Ayers LW, Ross P, Croce CM, Chakravarti A, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res. 2013; 19:5423-5433.
10. Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan M, Jeon YJ, Li B, Vicentini C, Peng Y, Lee TJ, Luo Z, Liu L, Xu D, Tili E, Jin V, et al. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci U S A. 2015.
11. Wang Y, Ren J, Gao Y, Ma JZ, Toh HC, Chow P, Chung AY, Ooi LL and Lee CG. MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PLoS One. 2013; 8:e68744.
12. Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, Ooi LL and Lee CG. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012; 26:3032-3041.
13. Liao WT, Li TT, Wang ZG, Wang SY, He MR, Ye YP, Qi L, Cui YM, Wu P, Jiao HL, Zhang C, Xie YJ, Wang JX and Ding YQ. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res. 2013; 19:4662-4672.
14. Huang L, Dai T, Lin X, Zhao X, Chen X, Wang C, Li X, Shen H and Wang X. MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochem Biophys Res Commun. 2012; 425:127-133.
15. Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa M, Naya Y, Ichikawa T and Seki N. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014; 588:1973-1982.
16. Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC, Ling XH, Fu X, Dai QS, Cai C, Chen JH, Liang YX, Jiang FN, Zhong WD, Wang F and Wu CL. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer. 2014; 135:541-550.
17. Li J and Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008; 27:6194-6206.
18. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K and Sasada M. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med. 1998; 187:587-600.
19. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol. 1999; 144:281-292.
20. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD and Mehta K. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002; 21:8843-8851.
21. Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer PH, Debatin KM and Herr I. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer. 2004; 108:580-587.
22. Volm M, Mattern J and Koomagi R. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas. Anticancer Res. 1999; 19:1669-1671.
23. Palmerini F, Devilard E, Jarry A, Birg F and Xerri L. Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma. Hum Pathol. 2001; 32:461-467.
24. Yoo NJ, Lee JW, Kim YJ, Soung YH, Kim SY, Nam SW, Park WS, Lee JY and Lee SH. Loss of caspase-2,-6 and-7 expression in gastric cancers. APMIS. 2004; 112:330-335.
25. Soung YH, Lee JW, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Park YG, Nam SW, Jeong SW, Kim SH, Lee JY, Yoo NJ and Lee SH. Inactivating mutations of CASPASE-7 gene in human cancers. Oncogene. 2003; 22:8048-8052.
26. Odonkor CA and Achilefu S. Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy. Cancer Invest. 2009; 27:417-429.
27. Lin YF, Lai TC, Chang CK, Chen CL, Huang MS, Yang CJ, Liu HG, Dong JJ, Chou YA, Teng KH, Chen SH, Tian WT, Jan YH, Hsiao M and Liang PH. Targeting the XIAP/caspase-7 complex selectively kills caspase-3-deficient malignancies. J Clin Invest. 2013; 123:3861-3875.
28. Gyorffy B, Surowiak P, Budczies J and Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8:e82241.
29. Liang M, Yao G, Yin M, Lu M, Tian H, Liu L, Lian J, Huang X and Sun F. Transcriptional cooperation between p53 and NF-kappaB p65 regulates microRNA-224 transcription in mouse ovarian granulosa cells. Mol Cell Endocrinol. 2013; 370:119-129.
30. Song YJ, Jen KY, Soni V, Kieff E and Cahir-McFarland E. IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation. Proc Natl Acad Sci U S A. 2006; 103:2689-2694.
31. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10:704-714.
32. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P and Lee CG. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 2008; 283:13205-13215.
33. Yu L, Zhang J, Guo X, Li Z and Zhang P. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma. Cancer Epidemiol. 2014; 38:408-413.
34. Adamopoulos PG, Kontos CK, Rapti SM, Papadopoulos IN and Scorilas A. miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. Int J Oncol. 2015; 46:849-859.
35. Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J and Yu L. Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients. Diagn Pathol. 2014; 9:198.
36. Wang H, Zhu LJ, Yang YC, Wang ZX and Wang R. MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G(1)/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer. 2014; 111:339-354.
37. Yoo SS, Choi JE, Lee WK, Choi YY, Kam S, Kim MJ, Jeon HS, Lee EB, Kim DS, Lee MH, Kim IS, Jheon S and Park JY. Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2009; 27:5823-5829.
38. McIlwain DR, Berger T and Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013; 5:a008656.
39. de Oca J, Azuara D, Sanchez-Santos R, Navarro M, Capella G, Moreno V, Sola A, Hotter G, Biondo S, Osorio A, Marti-Rague J and Rafecas A. Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. Int J Colorectal Dis. 2008; 23:21-27.
40. Sun Y, Chen XY, Liu J, Cheng XX, Wang XW, Kong QY and Li H. Differential caspase-3 expression in noncancerous, premalignant and cancer tissues of stomach and its clinical implication. Cancer Detect Prev. 2006; 30:168-173.
41. Winter RN, Kramer A, Borkowski A and Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001; 61:1227-1232.
42. Huang H, Zhang XF, Zhou HJ, Xue YH, Dong QZ, Ye QH and Qin LX. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010; 101:1314-1319.
43. Volm M and Koomagi R. Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. Oncol Rep. 2000; 7:95-98.
44. Soung YH, Lee JW, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ and Lee SH. Somatic mutations of CASP3 gene in human cancers. Hum Genet. 2004; 115:112-115.
45. Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Gronberg H, Hoyer S, Borre M, et al. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2014; 20:2169-2181.
46. Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D'Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M and Pediconi N. Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways. J Hepatol. 2012; 56:855-861.
47. Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, Bernard MD, Battaglia G, Parente P, Croce CM, Zaninotto G, Ancona E and Rugge M. MicroRNA expression profilling in human Barrett's carcinogenesis. Int J Cancer. 2011;129:1661-1670.